Antibodies, and methods for their use
AssigneeSurface Active Limited
InventorBeverley J. Randle
Life of this patent
Estimating the term…
Abstract
This invention relates to antibodies and is particularly, though not exclusively, concerned with diagnostic and therapeutic methods using monoclonal bi- or tri-specific antibodies. The invention also provides a method in which binding of a first antigen to a first antibody binding site causes release of a second antigen from an adjacent second antibody antigen binding site.
Claims30
An immunoassay method for determining the presence or absence of a first antigen in a sample, the method comprising:
- contacting the sample with at least one antibody arranged to provide a first and a second antigen binding site, said first antigen binding site being arranged to bind a first antigen and said second antigen binding site being arranged to bind a second antigen wherein binding of said first antigen to said first antigen binding site causes release of said second antigen bound to said second antigen binding site:
- and
- measuring the amount of second antigen released.
An immunoassay method for determining the presence or absence of an antigert in a sample, the method comprising:
- contacting the sample with a multispecific antibody having binding sites for the antigen and an enzyme, wherein binding of the enzyme to the antibody inactivates the enzyme, and wherein binding of the antigen to the antibody results in release of said enzyme in an active form from the antibody;
- and
- detecting the activity of the released enzyme which indicates the presence of the antigen in the sample.
A method of detecting lung surfactant apoprotein A in a sample of mammalian body fluid, comprising:
- contacting the sample with a multispecific antibody having binding sites for lung surfactant apoprotein A and an enzyme, wherein binding of the enzyme to the antibody inactivates the enzyme, and wherein binding of lung surfactant apoprotein A to the antibody results in release of said enzyme in an active form from the antibody;
- and
- detecting the activity of the released enzyme which indicates the presence of lung surfactant apoprotein A in the sample.
A kit for use in an immunoassay method, said kit comprising:
- a first antibody having a first and second antigen binding site for a first antigen and a second antigen, respectively, wherein said second antigen is an enzyme and binding to said second antigen binding site inactivates the enzymatic activity of the second antigen;
- a second antibody having:
- (a) a third antigen binding site for the second antigen or a reaction product of the second antigen, and (b) a fourth antigen binding site for a detectable third antigen;
- wherein binding of the first antigen to the first antibody causes release of the second antigen in an enzymatically active form, the released second antigen or a reaction product thereof being capable of binding to said second antibody, thereby causing release of said detectable third antigen from said second antibody.
A trispecific antibody for use in an immunoassay method, comprising:
- a first antigen binding site directed to a diagnostic marker, a second antigen binding site directed to a first enzyme, and a third antigen binding site directed to a second enzyme, wherein the first and second enzymes, when bound to the second and third antigen binding sites, are in an enzymatically inactive form, wherein upon binding of the diagnostic marker to the first antigen binding site the first and second enzymes are released from the second and third antigen binding sites in enzymatically active form, wherein a reaction product of the released second enzyme is a substrate for the released first enzyme, and said first enzyme produces a detectable reaction product.
A prebound complex consisting of a multispecific antibody and an enzyme, said multispecific antibody comprising binding sites for an antigen and an enzyme, wherein the enzyme is bound to and inactivated by binding to the antibody and wherein said enzyme can be released from the antibody in an active form upon binding of the antigen to the antibody.
A prebound complex consisting of a multispecific antibody and an enzyme, said multispecific antibody comprising binding sites for lung surfactant apoprotein A and an enzyme, wherein the enzyme is bound to and inactivated by binding to the antibody and wherein said enzyme can be released from the antibody in an active form upon binding of lung surfactant apoprotein A to the antibody.
The cell line GAL30.19 as deposited in accordance with the provisions of the Budapest Treaty at the European Collection of Animal Cell Cultures, Porton Down, United Kingdom, under the accession number 92042211.
Dependencies are inferred from the claim text.